A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir

A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir

Oral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the first agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. More recently, ombitasvir/paritaprevir/ritonavir is also recommend...

Full description

Bibliographic Details
Main Authors: Kazuo Tarao, Kouzo Yamada
Format: Article
Language:English
Published: Karger Publishers 2017-06-01
Series:Case Reports in Gastroenterology
Subjects:
Interstitial pneumonia
Direct-acting antivirals
Dry cough
Hepatitis C virus liver disease
Ombitasvir/paritaprevir/ritonavir
Online Access:http://prod.karger.com/Article/FullText/462965

Internet

http://prod.karger.com/Article/FullText/462965

Similar Items